Tathagata Chatterjee1, Venkatesan Somasundaram2. 1. Commandant, 166 Military Hospital, C/o 56 APO, India. 2. Assistant Professor, Dept of Pathology, Armed Forces Medical College, Pune 411040, India.
Abstract
BACKGROUND: Normal B lymphoid precursors that express CD19, CD10, and/or CD34 are highly sensitive to corticosteroids and after two weeks of remission-induction therapy, they form less than 0.01% of the bone marrow population. More than 0.01% of such cells indicate minimal residual disease (MRD). MRD "lite" panel uses only three antibodies, namely CD19, CD10, and CD34 for MRD detection in cases of B-lineage acute lymphoblastic leukemia (B-ALL) expressing CD19, CD10, and/or CD34 by flow cytometry. METHODS: Fifteen cases of B-ALL were studied for MRD at Day 19 of remission-induction therapy by employing a simplified MRD detection protocol using a 3-color fluorochrome conjugated antibody panel (CD19, CD10, and CD34) on bone marrow aspirate samples. RESULTS: All cases at diagnosis expressed CD19, CD10, and CD34. Of fifteen patients, five (33.33%) were MRD negative with less than 0.01% of mononuclear cells and remaining ten cases (66.66%) were MRD positive, with the level of 0.01% to less than 0.1% cells. CONCLUSION: The MRD assay used in this study is a simplified method for detecting MRD at Day 19 of remission-induction therapy for B-lineage ALL. This MRD assay is an effective and useful methodology in cases of B-ALL expressing CD19, CD10, and/or CD34 by flow cytometry.
BACKGROUND: Normal B lymphoid precursors that express CD19, CD10, and/or CD34 are highly sensitive to corticosteroids and after two weeks of remission-induction therapy, they form less than 0.01% of the bone marrow population. More than 0.01% of such cells indicate minimal residual disease (MRD). MRD "lite" panel uses only three antibodies, namely CD19, CD10, and CD34 for MRD detection in cases of B-lineage acute lymphoblastic leukemia (B-ALL) expressing CD19, CD10, and/or CD34 by flow cytometry. METHODS: Fifteen cases of B-ALL were studied for MRD at Day 19 of remission-induction therapy by employing a simplified MRD detection protocol using a 3-color fluorochrome conjugated antibody panel (CD19, CD10, and CD34) on bone marrow aspirate samples. RESULTS: All cases at diagnosis expressed CD19, CD10, and CD34. Of fifteen patients, five (33.33%) were MRD negative with less than 0.01% of mononuclear cells and remaining ten cases (66.66%) were MRD positive, with the level of 0.01% to less than 0.1% cells. CONCLUSION: The MRD assay used in this study is a simplified method for detecting MRD at Day 19 of remission-induction therapy for B-lineage ALL. This MRD assay is an effective and useful methodology in cases of B-ALL expressing CD19, CD10, and/or CD34 by flow cytometry.
Authors: T Flohr; A Schrauder; G Cazzaniga; R Panzer-Grümayer; V van der Velden; S Fischer; M Stanulla; G Basso; F K Niggli; B W Schäfer; R Sutton; R Koehler; M Zimmermann; M G Valsecchi; H Gadner; G Masera; M Schrappe; J J M van Dongen; A Biondi; C R Bartram Journal: Leukemia Date: 2008-01-31 Impact factor: 11.528
Authors: M Brüggemann; A Schrauder; T Raff; H Pfeifer; M Dworzak; O G Ottmann; V Asnafi; A Baruchel; R Bassan; Y Benoit; A Biondi; H Cavé; H Dombret; A K Fielding; R Foà; N Gökbuget; A H Goldstone; N Goulden; G Henze; D Hoelzer; G E Janka-Schaub; E A Macintyre; R Pieters; A Rambaldi; J-M Ribera; K Schmiegelow; O Spinelli; J Stary; A von Stackelberg; M Kneba; M Schrappe; J J M van Dongen Journal: Leukemia Date: 2009-12-24 Impact factor: 11.528
Authors: Valentino Conter; Claus R Bartram; Maria Grazia Valsecchi; André Schrauder; Renate Panzer-Grümayer; Anja Möricke; Maurizio Aricò; Martin Zimmermann; Georg Mann; Giulio De Rossi; Martin Stanulla; Franco Locatelli; Giuseppe Basso; Felix Niggli; Elena Barisone; Günter Henze; Wolf-Dieter Ludwig; Oskar A Haas; Giovanni Cazzaniga; Rolf Koehler; Daniela Silvestri; Jutta Bradtke; Rosanna Parasole; Rita Beier; Jacques J M van Dongen; Andrea Biondi; Martin Schrappe Journal: Blood Date: 2010-02-12 Impact factor: 22.113
Authors: Kirk R Schultz; D Jeanette Pullen; Harland N Sather; Jonathan J Shuster; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Jeffrey E Rubnitz; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Paul S Gaynon; Bruce M Camitta Journal: Blood Date: 2006-09-26 Impact factor: 22.113
Authors: V H J Van der Velden; L Corral; M G Valsecchi; M W J C Jansen; P De Lorenzo; G Cazzaniga; E R Panzer-Grümayer; M Schrappe; A Schrauder; C Meyer; R Marschalek; L L Nigro; M Metzler; G Basso; G Mann; M L Den Boer; A Biondi; R Pieters; J J M Van Dongen Journal: Leukemia Date: 2009-02-12 Impact factor: 11.528
Authors: V H J van der Velden; G Cazzaniga; A Schrauder; J Hancock; P Bader; E R Panzer-Grumayer; T Flohr; R Sutton; H Cave; H O Madsen; J M Cayuela; J Trka; C Eckert; L Foroni; U Zur Stadt; K Beldjord; T Raff; C E van der Schoot; J J M van Dongen Journal: Leukemia Date: 2007-02-08 Impact factor: 11.528
Authors: Michael Norbert Dworzak; Giuseppe Gaipa; Richard Ratei; Marinella Veltroni; Angela Schumich; Oscar Maglia; Leonid Karawajew; Allessandra Benetello; Ulrike Pötschger; Zvenyslava Husak; Helmut Gadner; Andrea Biondi; Wolf-Dieter Ludwig; Giuseppe Basso Journal: Cytometry B Clin Cytom Date: 2008-11 Impact factor: 3.058